Acipimox is a niacin derivative that acts as an anti-hyperlipidemic. Acipimox decreases levels of triglycerides, LDL, and free fatty acids, and increases levels of HDL. Acipimox decreases cAMP levels and AMPK activity, suppressing lipolysis by lipase.
| Cas No. | 51037-30-0 |
|---|---|
| Purity | ≥98% |
| Formula | C6H6N2O3 |
| Formula Wt. | 154.12 |
| Chemical Name | 5-Methylpyrazinecarboxylic acid 4-oxide |
| IUPAC Name | 5-methyl-4-oxidopyrazin-4-ium-2-carboxylic acid |
| Melting Point | 177-180°C |
| Solubility | Water 20 mg/mL |
| Appearance | Off-white crystalline powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Møller N, Gormsen LC, Schmitz O, et al. Free fatty acids inhibit growth hormone/signal transducer and activator of transcription-5 signaling in human muscle: a potential feedback mechanism. J Clin Endocrinol Metab. 2009 Jun;94(6):2204-7. PMID: 19276230.
Christie AW, McCormick DK, Emmison N, et al. Mechanism of anti-lipolytic action of acipimox in isolated rat adipocytes. Diabetologia. 1996 Jan;39(1):45-53. PMID: 8720602.
